COSMIC : A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Liver<br/>CancersCancer LocationLiver
Cancers

Systemic therapy | Stomach and upper gastrointestinal tractLiver

Trial Overview Read MoreRead more

This phase III trial is comparing the safety and effectiveness of a chemotherapy (cabozantinib) and immunotherapy drug (atezolizumab) combination, with a standard of care chemotherapy drug (sorafenib), in patients with advanced hepatocellular (liver) cancer who have not received prior treatment.
 

This trial is treating patients with hepatocellular (liver) cancer.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

Commercial Sponsor

Exelixis

Summary

Patients in this trial will be randomised into one of three treatment arms; the experimental arm, active comparator or the exploratory arm. In the experimental arm, patients with advanced hepatocellular cancer (HCC) will be given 40mg of oral cabozantinib daily and a 1200 mg intravenous dose atezolizumab every three weeks. In the comparator arm, patients will receive 400mg of oral sorafenib twice a day. Patients in the exploratory arm will be given 60mg of oral cabozantinib once daily.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Not Recruiting Hospitals Read MoreRead more

Not currently recruiting

Royal Melbourne Hospital, Colorectal Medicine / Gastroenterology
Parkville
Ms Virginia Bird
virginia.bird@mh.org.au
03 9342 7798

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next